PASSAGE BIO, INC.

PASG ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $-45.5M $-64.8M $-102.1M $-136.1M $-185.4M $-112.2M $-45.6M
Depreciation & Amortization $728.0K $3.1M $3.7M $3.7M $1.5M $800.0K $134.0K
Depreciation
Amortization
Stock-Based Compensation $3.0M $5.8M $10.9M $19.0M $32.7M $14.6M $1.5M
Net Cash from Operating Activities $-31.5M $-48.0M $-78.3M $-118.2M $-126.9M $-80.5M $-39.9M
Investing Activities
Capital Expenditures $34.0K
Business Acquisitions
Net Cash from Investing Activities $40.2M $54.9M $65.2M $25.2M $-45.8M $-172.1M $-1.7M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $23.0K $8.9M $135.0K $-1.4M $166.7M $228.8M $175.6M
Net Change in Cash $8.7M $15.9M $-12.9M $-94.4M $-6.0M $-23.9M $134.0M
Free Cash Flow $-48.0M